tranexamic acid has been researched along with Sinus Infections in 4 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranexamic acid is an antifibrinolytic that is known to reduce operative bleeding." | 2.78 | Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial. ( Chiarella, A; Côté, DW; Dziegielewski, PT; Langille, MA; Mulholland, G; Sowerby, LJ; Wright, ED, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achour, I | 1 |
| Ben Rhaiem, Z | 1 |
| Thabet, W | 1 |
| Jdidi, J | 1 |
| Mnejja, M | 1 |
| Hammami, B | 1 |
| Chakroun, A | 1 |
| Charfeddine, I | 1 |
| Jahanshahi, J | 1 |
| Hashemian, F | 1 |
| Pazira, S | 1 |
| Bakhshaei, MH | 1 |
| Farahani, F | 1 |
| Abasi, R | 1 |
| Poorolajal, J | 1 |
| Alimian, M | 1 |
| Mohseni, M | 1 |
| Langille, MA | 1 |
| Chiarella, A | 1 |
| Côté, DW | 1 |
| Mulholland, G | 1 |
| Sowerby, LJ | 1 |
| Dziegielewski, PT | 1 |
| Wright, ED | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial[NCT04863339] | Phase 2 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to Challenges in recruitment) | ||
| Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery[NCT04754230] | Phase 4 | 40 participants (Actual) | Interventional | 2021-06-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient-reported Visual Analog Scale - Bleeding Score Day 1. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 1 (assessed within first 24 hours following surgery)
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 5.03 |
| 1,000mg IV Tranexamic Acid | 4.82 |
Patient-reported Visual Analog Scale - Bleeding Score Day 2. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 4.47 |
| 1,000mg IV Tranexamic Acid | 3.89 |
Patient-reported Visual Analog Scale - Bleeding Score Day 3. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 3
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.93 |
| 1,000mg IV Tranexamic Acid | 2.29 |
Patient-reported Visual Analog Scale - Bleeding Score Day 4. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 4
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.12 |
| 1,000mg IV Tranexamic Acid | 1.44 |
Patient-reported Visual Analog Scale - Bleeding Score Day 5. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 5
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.32 |
| 1,000mg IV Tranexamic Acid | 1.15 |
Patient-reported Visual Analog Scale - Bleeding Score Day 6. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 6
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.36 |
| 1,000mg IV Tranexamic Acid | 0.76 |
Patient-reported Visual Analog Scale - Bleeding Score Day 7. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 7
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 0.97 |
| 1,000mg IV Tranexamic Acid | 0.72 |
Number of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse (in PACU), had any follow-up visit or phone call outside of regularly scheduled follow-up (NCT04754230)
Timeframe: Day of surgery through 1 week
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PACU | Follow-up visit | Follow-up phone call | |
| 1,000mg IV Tranexamic Acid | 0 | 1 | 2 |
| Normal Saline | 0 | 0 | 2 |
Patient-reported Visual Analog Scale - Guaze Saturation Score through Postoperative Day 7. Score range: 0 (not at all) to 10 (dripping blood). (NCT04754230)
Timeframe: Postoperative Day 2 through Postoperative Day 7
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | Postoperative day 5 | Postoperative day 6 | Postoperative day 7 | |
| 1,000mg IV Tranexamic Acid | 4.56 | 2.09 | 0.76 | 0.40 | 0.29 | 0.28 |
| Normal Saline | 5.16 | 3.03 | 1.74 | 1.11 | 0.99 | 0.80 |
4 trials available for tranexamic acid and Sinus Infections
| Article | Year |
|---|---|
The Effect of Topical Tranexamic Acid in Endoscopic Sinus Surgery: A Triple Blind Randomized Clinical Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Endoscopy; Humans; Sinusitis; Tr | 2023 |
Effect of topical tranexamic acid on bleeding and quality of surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple blind randomized clinical trial.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Chronic D | 2014 |
The effect of intravenous tranexamic acid on blood loss and surgical field quality during endoscopic sinus surgery: a placebo-controlled clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Endoscopy; Female; Hospit | 2011 |
Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Chemotherapy, | 2013 |